Tenderwize
Retour à la recherche

Omalizumab Discount Agreement Open House

Techniker Krankenkasse·Hamburg, Germany·Deadline Jun 30, 2028 · 674 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 18 Omalizumab

60/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

60 / 100

Complexité

20 / 100

Facteurs de risque

No indication of estimated contract value or expected volume; revenue depends on actual prescriptions and number of par...

The notice explicitly states this is not a public procurement under EU directives; legal remedies lie with social court...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Jun 2028
  • Conclusion of discount agreements (Rabattverträge) for the active substance Omalizumab
  • Standardized contract terms no individualized negotiations
Afficher le résumé complet

Open house procedure by Techniker Krankenkasse (TK) for discount agreements (Rabattverträge) on the active substance Omalizumab. The procedure allows any qualified pharmaceutical entrepreneur to join at any time during the contract term (max 24 months until 30.06.2028). No exclusivity, no individual negotiations, and no estimated value provided. Eligibility requires being a pharmaceutical entrepreneur with a valid marketing authorization for the product. Award criteria are not specified. Submission is via email (with qualified electronic signature) or postal mail. Important: This is not a public procurement in the traditional sense; legal remedies lie with social courts, not procurement chambers.

Risques

No indication of estimated contract value or expected volume; revenue depends on actual prescriptions and number of par...

The notice explicitly states this is not a public procurement under EU directives; legal remedies lie with social court...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur under § 4 Abs. 18 AMG with a valid marketing authorization for Omalizumab

Eligibility

  • Must submit a self-declaration (Anlage 4) confirming eligibility and reliability

Administrative

  • Contract can be signed at any time during the term but for timely inclusion in pharmacy software documents must be received by the 3rd of the previous month

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria specified; the procedure is open to all qualified participants with standardized conditions.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Omalizumab Discount Agreement Open House

Single lot covering all discount agreements for Omalizumab. The TK aims to conclude rebate contracts with all eligible pharmaceutical entrepreneurs under § 130a Abs. 8 SGB V.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Jun 2026 - Jun 2028

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria specified; the procedure is open to all qualified participants with standardized conditions.

Date limite

Deadline Jun 30, 2028

Détails de la procédure

Date de publication
20 May 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
349347-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3